Answers are grounded in this paper and cite their sources.
Retrospective cohort study reports predictors for pCR and DFS in HER2-positive breast cancer, suggesting personalized NAC regimens.
Neoadjuvant chemotherapy (NAC) combined with anti-HER-2 therapy is the standard for HER-2-positive breast cancer (BC), and yield high pathological complete response (pCR) and favorable prognosis. However, real-world impacts of different anti-HER-2 strategies on pCR and disease-free survival (DFS) remain unclear. his retrospective study enrolled 837 HER-2-positive BC patients who received NAC plus anti-HER-2 therapy (Jan 2020–Dec 2024) followed by surgery. Clinical, biological, pathological and anti-HER-2 regimen data were collected. Logistic regression analyzed factors associated with pCR, and Cox regression identified independent DFS predictors. The overall pCR rate was 44.32% (371 cases). Multivariate analysis showed clinical stage, HER-2 status, and HR status significantly correlated with pCR. Stage III patients had significantly lower total pCR (tpCR) and breast pCR (bpCR) than stage I-II patients (P = 0.003, P = 0.005); ER/PR-negative patients had significantly higher tpCR/bpCR than HR-positive patients (all P < 0.05). HER-2 3+ patients had significantly higher tpCR/bpCR than HER-2 2+ patients (all P < 0.001). During follow-up, 74 patients suffered recurrence/metastasis. pCR was significantly associated with better DFS (P < 0.0001), and anti-HER-2 regimens significantly affected DFS (P = 0.035). Multivariate Cox regression confirmed age (HR = 1.04), clinical stage (III vs I-II, HR = 3.4), tpCR (HR = 0.2), and chemotherapy regimen (THP-EC vs TCbHP, HR = 0.34) as independent predictors of DFS (all P < 0.05). Compared with TCbHP, THP-EC and THPy reduced DFS event risk (OR = 0.30, 0.19), while AC-THP and THP showed no significant differences. Clinical stage, HR status, and HER-2 expression predict pCR in HER-2-positive BC patients receiving NAC. Despite comparable pCR efficacy, THP-EC and THPy may have prognostic advantages over TCbHP, supporting personalized NAC selection. Prospective studies are needed to confirm the optimal treatment. • Our study enrolled a total of 837 female patients diagnosed with stage I-III HER-2 positive BC who received NAC. • Clinical stage, HR status and HER-2 expression were key predictors of pCR in HER-2-positive BC patients receiving NAC. • Different anti-HER2 regimens had comparable pCR efficacy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: